SCHEMBL2952196

SCHEMBL2952196

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 4/20 0.52
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALOX5 P09917 2/20 0.44
PTGES O14684 1/20 0.43
DHODH Q02127 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953098 0.91 MAPT (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1266606 0.90 MAPT (0.49) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2954053 0.90 DHODH (0.50) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL1266134 0.88 DHODH (0.44) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1266980 0.86 FNTA (0.46) MAPTALDH1A1MEN1KMT2ALMNA
Ammonia Solution, Strong SCHEMBL2960320 0.86 NPC1 (0.41) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1267006 0.86 DHODH (0.44) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL2956411 0.86 TOP2A (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL1265977 0.86 MAPT (0.42) MAPTALDH1A1KDM4ENPC1HTT
SCHEMBL2952784 0.85 NPC1 (0.41) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK MAPT 4305/4885ALDH1A1 1045/4885KDM4E 2174/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 MAPT 4495/4885ALDH1A1 717/4885KDM4E 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.